...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Cancer >Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay
【24h】

Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay

机译：CYFRA 21-1酶免疫法测定细胞角蛋白19片段作为肺癌的标志物

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Soluble cytokeratin fragment 19 levels were measured with an enzyme immunoassay method developed by Boehringer Mannheim (Enzymun-Test CYFRA 21-1) in the serum of 185 patients with lung cancer [149 with non-small-cell lung cancer (NSCLC) and 36 with small-cell lung cancer (SCLC)] and 97 patients with benign lung diseases in order to determine its clinical usefulness in the diagnosis of lung cancer and follow-up of treatment. We used the cut-off value of 3.5 ng ml-1, established by the Japan CYFRA research group. This cut-off value is based on calculations using the receiver operating characteristic approach instead of using the 95% specificity approach recommended by other authors. The resulting sensitivity and specificity for the group of all lung cancer patients were 65.4% and 84.5% respectively. The sensitivity was highest (76.1%) for squamous cell carcinoma and lowest (44.4%) for SCLC. For NSCLC patients, when CYFRA 21-1 levels were analysed by node (N) factor, patients who presented with mediastinal lymph node metastasis (N2 or N3) demonstrated higher serum CYFRA 21-1 levels (5.6; interquartile range 3.2-11.5 ng ml-1) than patients without mediastinal node metastasis (N0 or N1, 3.9; interquartile range 2.2-10.0 ng ml-1; Mann-Whitney U-test, P = 0.0373). We compared the discriminatory power of CYFRA 21-1 with that of other tumour markers including carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC) and neuron-specific enolase (NSE). The area under the curve (AUC) of each ROC curve was calculated using the CLABROC program for statistical analysis. CYFRA 21-1 appeared to have the most discriminatory power of the markers tested in the diagnosis of lung cancer. In serial measurements of 14 patients receiving chemotherapy or radiotherapy, a high degree of correlation was noted between serum levels of CYFRA 21-1 and extent of clinical response (Wilcoxon, P = 0.0093).
机译：用Boehringer Mannheim（Enzymun-Test CYFRA 21-1）开发的酶免疫测定法测量了185例肺癌患者[149例非小细胞肺癌（NSCLC）和36例肺癌患者]的血清中可溶性细胞角蛋白片段19的水平。小细胞肺癌（SCLC）]和97例肺良性疾病患者，以确定其在肺癌诊断和后续治疗中的临床价值。我们使用了日本CYFRA研究小组确定的3.5 ng ml-1的临界值。该临界值基于使用接收器工作特征方法的计算，而不是使用其他作者推荐的95％特异性方法。所有肺癌患者组的敏感性和特异性分别为65.4％和84.5％。鳞状细胞癌的敏感性最高（76.1％），而SCLC的最低（44.4％）。对于非小细胞肺癌患者，当通过淋巴结（N）因子分析CYFRA 21-1水平时，纵隔淋巴结转移（N2或N3）的患者血清CYFRA 21-1水平较高（5.6;四分位间距为3.2-11.5 ng / ml） -1）比无纵隔淋巴结转移的患者（N0或N1，3.9;四分位间距2.2-10.0 ng ml-1; Mann-Whitney U检验，P = 0.0373）。我们比较了CYFRA 21-1与其他肿瘤标记物（包括癌胚抗原（CEA），鳞状细胞癌抗原（SCC）和神经元特异性烯醇化酶（NSE））的鉴别力。使用CLABROC程序进行统计分析，计算每个ROC曲线的曲线下面积（AUC）。 CYFRA 21-1似乎具有在肺癌诊断中测试的最具标志性的标记。在对接受化疗或放疗的14位患者进行的系列测量中，发现CYFRA 21-1的血清水平与临床反应程度之间存在高度相关性（Wilcoxon，P = 0.0093）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号